Research Article

Corticosteroids for Graves’ Ophthalmopathy: Systematic Review and Meta-Analysis

Table 2

Methodological quality of randomized clinical trials included in the meta-analysis.

StudyAllocation generation;  concealmentBindingFollow-up lost (n)ITTSelective ReportingUnequal baseline or other remarks
ParticipantsInvestigatorsExaminers

van Geest2008A, AYNY1 at week 0YNA
Lee2012A, BNNY10NNSwelling grade
Salvi2015A, BYNY1NYProtocol amendment
Savino2014B, BNNN1NNA
Prummel1993A, BYNY3NNA
Prummel1989A, BNNY0YNA
Stamato2006A, BYNY3NNA
Kahaly1996A, BNNY0YNAVisual acuity
Ye2016A, BNNY16NNA
Kung1996A, BNNY0YNACAS
Kahaly1986C, CNNY0YNA
Kahaly2018A, ANYY23NN
Chen 2016A, BNNN0YNA
Kahaly1990B, BYNY0YNA
Ng2005B, BNNY1NNAAge
Pinchera1987A, BNNN0YNA
Rajendram2018A, BYYY69YNEthnicity
Roy2015A, BNNN3NNDiplopia, TSH
Macchia2001B, BNNN0YNACAS, OI
Akarsu2011B, BNNN0YNA
Aktaran2007A, ANNY0YNALid width
Kahaly2005A, BNNY0YNALid width
Kauppinen-Makelin2002A, ANNN0YNATSab titers, visual acuity
Marcocci2001A, BNNY0YNA
Alkawas2010B, BNNN5NNA
Bartalena2012A, AYNY6YNAAge, gender
He2016A, BNNY8NNA
Zhu2014A, ANNN2YNADuration of eye symptoms; TRAb
Philip 2013B, BNNN0YNA

ITT: intention to treat analysis; A: adequate; B: unknown; C: inadequate; N: no; Y: yes; NA: unable to assess; CAS: clinical activity score; TSH: thyroid stimulating hormone; OI: ophthalmopathy index score; TSab: thyroid stimulating antibodies; TRAb: TSH receptor antibody.